Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

Journal of Crohn's and Colitis

Volumn 5, Issue 4, 2011, Pages 324-331

  Sprakes, Michael B ^a   Hamlin, P John ^a   Warren, Lisa ^a   Greer, Dan ^a   Ford, Alexander C ^a,b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Adalimumab; Biological therapy; Crohn's disease2

Indexed keywords

ACICLOVIR; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; JAW PAIN; MALE; MOUTH INFECTION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79958859979     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.02.007     Document Type: Article

References (33)

1. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
2. Munkholm P., Langholz E., Davidsen, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
3. Andoh Akira, Yagi Yuhki, Shioya Makoto, et al. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008, 14:5154-5161.
4. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000, 51:289-298.
5. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. ACCENT I study group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
7. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
8. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., Li J., Pollack P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
9. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., Pollack P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
10. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
11. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
12. Emi Aikawa N., de Carvalho J.F., Artur Almeida Silva C. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38:82-89.
13. Haraoui B., Cameron L., Ouellet M., White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006, 33:31-36.
14. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
15. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., D'Haens G., Li J., Rosenfeld M.R., Kent J.D., Pollack P.F. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomised trial. Ann Intern Med 2007, 146:829-838.
16. Russo E.A., Iaccuni M., Lindsay J.O., et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010, 22:334-339.
17. Lichenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality associated with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
18. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenecity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
19. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
20. Hinojosa J., Gomollón F., García S., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007, 25:409-418.
21. Narula N., Fedorak R.N. Does smoking reduce infliximab's effectiveness against Crohn's disease?. Can J Gastroenterol 2009, 23:121-125.
22. Ho G.T., Mowat A., Potts L., et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009, 29:527-534.
23. Sandborn W.J., Hanauer S., Loftus E.V., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:1984-1989.
24. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
25. Ho G.T., Smith L., Aitken S., Lee H.M., et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008, 27:308-315.
26. Oussalah A., Babouri A., Chevaux J.B., et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009, 29:416-423.
27. Peyrin-Biroulet L., Laclotte C., Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007, 25:675-680.
28. Seiderer J., Brand S., Dambacher J., et al. Adalimumab in patients with Crohns disease - safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007, 25:787-796.
29. Panaccione R., Sandborn W.J., DHaens G., et al. Adalimumab maintains long-term remission in moderately to severely active Crohns disease after infliximab failure. 1-year follow-up of the GAIN trial. Gastroenterology 2008, 134:A133.
30. Lichtiger S., Binion D.G., Wolf D.C., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
31. Swoger J.M., Loftus E.V., Tremaine W.J., et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010, 16:1912-1921.
32. Swaminath A., Ullman T., Rosen M., et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009, 29:273-278.
33. Youdim A., Vasiliauskas E.A., Targan S.R., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004, 10:333-338.